S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Laser breakthrough could send stock soaring 2,467% (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Laser breakthrough could send stock soaring 2,467% (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Laser breakthrough could send stock soaring 2,467% (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Laser breakthrough could send stock soaring 2,467% (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
NASDAQ:RGNX

REGENXBIO (RGNX) Stock Forecast, Price & News

$18.56
+1.33 (+7.72%)
(As of 06/1/2023 ET)
Compare
Today's Range
$17.05
▼
$18.82
50-Day Range
$17.23
▼
$21.71
52-Week Range
$17.02
▼
$35.73
Volume
430,858 shs
Average Volume
417,700 shs
Market Capitalization
$806.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

REGENXBIO MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
115.5% Upside
$40.00 Price Target
Short Interest
Bearish
12.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.81mentions of REGENXBIO in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.31) to ($2.46) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

997th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

151st out of 330 stocks

See Top Rated MarketRank™ Stocks Here

RGNX stock logo

About REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

June 1, 2023 | finance.yahoo.com
REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference
June 1, 2023 | americanbankingnews.com
REGENXBIO (NASDAQ:RGNX) versus Vaxcyte (NASDAQ:PCVX) Critical Survey
June 2, 2023 | Legacy Research (Affiliate) (Ad)
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
May 27, 2023 | americanbankingnews.com
REGENXBIO (NASDAQ:RGNX) Shares Down 7.5%
May 23, 2023 | seekingalpha.com
Regenxbio's gene therapy for Hunter syndrome gets FDA regenerative medicine status
May 23, 2023 | finance.yahoo.com
REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome
May 22, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on REGENXBIO (NASDAQ:RGNX)
May 22, 2023 | americanbankingnews.com
REGENXBIO Inc. (NASDAQ:RGNX) Receives $40.00 Consensus Target Price from Analysts
June 2, 2023 | Legacy Research (Affiliate) (Ad)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
May 17, 2023 | americanbankingnews.com
REGENXBIO (NASDAQ:RGNX) Shares Up 8.8%
May 16, 2023 | finance.yahoo.com
REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio
May 12, 2023 | msn.com
Regenxbio: Buy, High-Potential Stock Stagnant Due To No Near-Term Catalysts
May 12, 2023 | msn.com
Regenxbio's Return On Capital Employed Insights
May 10, 2023 | markets.businessinsider.com
Analyst Expectations for Regenxbio's Future
May 10, 2023 | msn.com
Morgan Stanley Maintains Regenxbio (RGNX) Overweight Recommendation
May 8, 2023 | americanbankingnews.com
REGENXBIO (NASDAQ:RGNX) PT Lowered to $55.00
May 7, 2023 | americanbankingnews.com
REGENXBIO (NASDAQ:RGNX) Stock Price Down 5.8% Following Analyst Downgrade
May 6, 2023 | americanbankingnews.com
REGENXBIO (NASDAQ:RGNX) Shares Gap Down After Earnings Miss
May 5, 2023 | americanbankingnews.com
REGENXBIO (NASDAQ:RGNX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS
May 3, 2023 | finance.yahoo.com
REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
May 2, 2023 | finance.yahoo.com
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting
May 1, 2023 | americanbankingnews.com
REGENXBIO (RGNX) Scheduled to Post Quarterly Earnings on Wednesday
April 26, 2023 | finance.yahoo.com
REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights
April 25, 2023 | americanbankingnews.com
REGENXBIO Inc. (NASDAQ:RGNX) Receives $40.86 Consensus Price Target from Analysts
April 18, 2023 | finance.yahoo.com
REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 15, 2023 | americanbankingnews.com
Head-To-Head Survey: Vaxart (NASDAQ:VXRT) versus REGENXBIO (NASDAQ:RGNX)
April 12, 2023 | markets.businessinsider.com
REGENXBIO: FDA Grants Fast Track Designation For RGX-202
See More Headlines

RGNX Price History

RGNX Company Calendar

Last Earnings
5/03/2023
Today
6/02/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
CUSIP
N/A
CIK
1590877
Web
www.regenxbio.com
Phone
(240) 552-8181
Fax
N/A
Employees
372
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.00
High Stock Price Forecast
$61.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+115.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($6.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-280,320,000.00
Net Margins
-246.50%
Pretax Margin
-246.54%
Return on Equity
-49.69%
Return on Assets
-31.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.46
Quick Ratio
3.46

Sales & Book Value

Annual Sales
$112.72 million
Price / Sales
7.16
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.70 per share
Price / Book
1.73

Miscellaneous

Outstanding Shares
43,470,000
Free Float
37,946,000
Market Cap
$806.80 million
Optionable
Optionable
Beta
1.08

Key Executives

  • Kenneth T. MillsKenneth T. Mills
    President, Chief Executive Officer & Director
  • Curran M. Simpson
    Chief Operating Officer
  • Vit Vasista
    Chief Financial Officer & Senior Vice President
  • Jerome W. Jackson
    Vice President-Information Technology
  • Olivier Danos
    Chief Scientific Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RGNX Stock - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings or view top-rated stocks.

What is REGENXBIO's stock price forecast for 2023?

7 Wall Street research analysts have issued twelve-month target prices for REGENXBIO's stock. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they expect the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 115.5% from the stock's current price.
View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2023?

REGENXBIO's stock was trading at $22.68 at the start of the year. Since then, RGNX stock has decreased by 18.2% and is now trading at $18.56.
View the best growth stocks for 2023 here.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our RGNX earnings forecast.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Wednesday, May, 3rd. The biotechnology company reported ($1.53) earnings per share for the quarter, missing analysts' consensus estimates of ($1.52) by $0.01. The biotechnology company had revenue of $19.10 million for the quarter, compared to analyst estimates of $31.29 million. REGENXBIO had a negative net margin of 246.50% and a negative trailing twelve-month return on equity of 49.69%. REGENXBIO's quarterly revenue was down 14.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.62) earnings per share.

What ETFs hold REGENXBIO's stock?

ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), WisdomTree BioRevolution Fund (WDNA), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco S&P SmallCap Health Care ETF (PSCH) and Invesco Raymond James SB-1 Equity ETF (RYJ).

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.50%), JPMorgan Chase & Co. (9.21%), State Street Corp (5.94%), Dimensional Fund Advisors LP (3.53%), Geode Capital Management LLC (1.75%) and First Manhattan CO. LLC. (1.03%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $18.56.

How much money does REGENXBIO make?

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $806.80 million and generates $112.72 million in revenue each year. The biotechnology company earns $-280,320,000.00 in net income (profit) each year or ($6.24) on an earnings per share basis.

How many employees does REGENXBIO have?

The company employs 372 workers across the globe.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.

This page (NASDAQ:RGNX) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -